{"product_id":"mrk-marketing-mix","title":"Merck \u0026 Co., Inc. (MRK): Marketing Mix Analysis [June-2026 Updated]","description":"\u003cp\u003eThis ready-made analysis gives you a clear, research-based view of Merck \u0026amp; Co., Inc. Business as of late 2025, showing how its portfolio is built around Keytruda, Gardasil 9, Winrevair, Capvaxive, and a late-stage pipeline in oncology, hematology, and virology; how it reaches customers across \u003cstrong\u003e140+\u003c\/strong\u003e countries and \u003cstrong\u003e5\u003c\/strong\u003e reporting regions under the MSD name outside the U.S. and Canada; how ASCO, ACC, FDA and EU filings, plus partnerships with Moderna, Mayo Clinic, and NVIDIA support promotion; and how premium pricing, the \u003cstrong\u003eJanuvia\u003c\/strong\u003e IRA discount, and generic and biosimilar pressure shape margins and market position.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eMerck \u0026amp; Co., Inc. - Marketing Mix: Product\u003c\/h2\u003e\n\u003cp\u003eMerck \u0026amp; Co., Inc. was still highly concentrated in \u003cstrong\u003eKeytruda\u003c\/strong\u003e and \u003cstrong\u003eGardasil\/Gardasil 9\u003c\/strong\u003e, which together generated \u003cstrong\u003e$33.9B\u003c\/strong\u003e in 2023, or \u003cstrong\u003e56.4%\u003c\/strong\u003e of total revenue of \u003cstrong\u003e$60.1B\u003c\/strong\u003e. \u003cstrong\u003eWinrevair\u003c\/strong\u003e and \u003cstrong\u003eCapvaxive\u003c\/strong\u003e are the newest commercial products, and they matter because they widen the portfolio beyond oncology and vaccines.\u003c\/p\u003e\n\n\u003ctable\u003e\n  \u003ctr\u003e\n    \u003cth\u003eProduct\u003c\/th\u003e\n    \u003cth\u003e2023 sales\u003c\/th\u003e\n    \u003cth\u003eShare of $60.1B\u003c\/th\u003e\n    \u003cth\u003eProduct role\u003c\/th\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eKeytruda\u003c\/td\u003e\n    \u003ctd\u003e$25.0B\u003c\/td\u003e\n    \u003ctd\u003e41.6%\u003c\/td\u003e\n    \u003ctd\u003eFlagship immuno-oncology product\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eGardasil\/Gardasil 9\u003c\/td\u003e\n    \u003ctd\u003e$8.9B\u003c\/td\u003e\n    \u003ctd\u003e14.8%\u003c\/td\u003e\n    \u003ctd\u003eAnchor vaccine franchise\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eCombined\u003c\/td\u003e\n    \u003ctd\u003e$33.9B\u003c\/td\u003e\n    \u003ctd\u003e56.4%\u003c\/td\u003e\n    \u003ctd\u003eCore product concentration\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eOther products and business lines\u003c\/td\u003e\n    \u003ctd\u003e$26.2B\u003c\/td\u003e\n    \u003ctd\u003e43.6%\u003c\/td\u003e\n    \u003ctd\u003eRemaining portfolio\u003c\/td\u003e\n  \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eKeytruda\u003c\/strong\u003e is pembrolizumab, an anti-PD-1 monoclonal antibody sold as a \u003cstrong\u003e100 mg\/4 mL\u003c\/strong\u003e intravenous concentrate. Adult dosing includes \u003cstrong\u003e200 mg every 3 weeks\u003c\/strong\u003e and \u003cstrong\u003e400 mg every 6 weeks\u003c\/strong\u003e. The product matters because it gives Merck \u0026amp; Co., Inc. a large, diversified cancer franchise rather than a single-tumor therapy.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eKeytruda\u003c\/strong\u003e also sets the revenue base for the product mix. A single product at \u003cstrong\u003e$25.0B\u003c\/strong\u003e in annual sales gives Merck \u0026amp; Co., Inc. strong scale, but it also creates concentration risk, which is why new launches and pipeline assets matter for the marketing mix.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eGardasil\u003c\/strong\u003e and \u003cstrong\u003eGardasil 9\u003c\/strong\u003e are the vaccine anchor. Merck \u0026amp; Co., Inc. reported \u003cstrong\u003e$8.9B\u003c\/strong\u003e in 2023 sales for the franchise. Gardasil 9 protects against \u003cstrong\u003e9\u003c\/strong\u003e HPV types, and the U.S. product is used in ages \u003cstrong\u003e9 to 45\u003c\/strong\u003e. The main presentation is a \u003cstrong\u003e0.5 mL\u003c\/strong\u003e intramuscular dose.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eGardasil 9\u003c\/strong\u003e matters because it is preventive, not therapeutic. That gives Merck \u0026amp; Co., Inc. a product with long-duration public health demand and a different customer base from oncology, which helps smooth the company’s product mix.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eWinrevair\u003c\/strong\u003e is the newest major franchise in pulmonary arterial hypertension. It received U.S. approval on \u003cstrong\u003eMarch 26, 2024\u003c\/strong\u003e, for adults with PAH. The labeled regimen starts at \u003cstrong\u003e0.3 mg\/kg\u003c\/strong\u003e and moves to \u003cstrong\u003e0.7 mg\/kg\u003c\/strong\u003e every \u003cstrong\u003e3 weeks\u003c\/strong\u003e. It expands Merck \u0026amp; Co., Inc. beyond cancer and vaccines into chronic specialty care.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eCapvaxive\u003c\/strong\u003e broadened the adult vaccine portfolio in \u003cstrong\u003e2024\u003c\/strong\u003e. It is a \u003cstrong\u003e21-valent\u003c\/strong\u003e pneumococcal conjugate vaccine approved for adults \u003cstrong\u003e18 years and older\u003c\/strong\u003e. The dose is \u003cstrong\u003e0.5 mL\u003c\/strong\u003e intramuscularly. This product gives Merck \u0026amp; Co., Inc. another preventive-care asset with a different clinical use than Gardasil 9.\u003c\/p\u003e\n\n\u003ctable\u003e\n  \u003ctr\u003e\n    \u003cth\u003eProduct\u003c\/th\u003e\n    \u003cth\u003eType\u003c\/th\u003e\n    \u003cth\u003eNumeric product features\u003c\/th\u003e\n    \u003cth\u003eU.S. approval date\u003c\/th\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eKeytruda\u003c\/td\u003e\n    \u003ctd\u003ePD-1 monoclonal antibody\u003c\/td\u003e\n    \u003ctd\u003e100 mg\/4 mL; 200 mg every 3 weeks; 400 mg every 6 weeks\u003c\/td\u003e\n    \u003ctd\u003eSeptember 4, 2014\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eGardasil 9\u003c\/td\u003e\n    \u003ctd\u003eProphylactic HPV vaccine\u003c\/td\u003e\n    \u003ctd\u003e9 HPV types; 0.5 mL; ages 9 to 45\u003c\/td\u003e\n    \u003ctd\u003eDecember 10, 2014\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eWinrevair\u003c\/td\u003e\n    \u003ctd\u003ePAH therapy\u003c\/td\u003e\n    \u003ctd\u003e0.3 mg\/kg; 0.7 mg\/kg every 3 weeks\u003c\/td\u003e\n    \u003ctd\u003eMarch 26, 2024\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eCapvaxive\u003c\/td\u003e\n    \u003ctd\u003e21-valent pneumococcal conjugate vaccine\u003c\/td\u003e\n    \u003ctd\u003e0.5 mL; adults 18 years and older\u003c\/td\u003e\n    \u003ctd\u003eJune 17, 2024\u003c\/td\u003e\n  \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cul class=\"lst_crct\"\u003e\n  \u003cli\u003eKeytruda sales: \u003cstrong\u003e$25.0B\u003c\/strong\u003e in 2023\u003c\/li\u003e\n  \u003cli\u003eGardasil\/Gardasil 9 sales: \u003cstrong\u003e$8.9B\u003c\/strong\u003e in 2023\u003c\/li\u003e\n  \u003cli\u003eKeytruda plus Gardasil\/Gardasil 9: \u003cstrong\u003e$33.9B\u003c\/strong\u003e in 2023\u003c\/li\u003e\n  \u003cli\u003eCombined share of Merck \u0026amp; Co., Inc. revenue: \u003cstrong\u003e56.4%\u003c\/strong\u003e\n\u003c\/li\u003e\n  \u003cli\u003eOther products and business lines: \u003cstrong\u003e$26.2B\u003c\/strong\u003e in 2023\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eLate-stage pipeline\u003c\/strong\u003e still spans oncology, hematology, and virology. Oncology is the clearest expansion area, with \u003cstrong\u003esacituzumab tirumotecan\u003c\/strong\u003e in phase 3 development. Virology includes \u003cstrong\u003eclesrovimab\u003c\/strong\u003e, Merck \u0026amp; Co., Inc.'s long-acting RSV antibody program. Hematology remains part of the broader development base and supports future diversification away from the current concentration in Keytruda and Gardasil.\u003c\/p\u003e\n\n\u003cul class=\"lst_crct\"\u003e\n  \u003cli\u003eOncology: \u003cstrong\u003esacituzumab tirumotecan\u003c\/strong\u003e in phase 3 development\u003c\/li\u003e\n  \u003cli\u003eVirology: \u003cstrong\u003eclesrovimab\u003c\/strong\u003e in late-stage development for RSV prevention\u003c\/li\u003e\n  \u003cli\u003eHematology: late-stage blood-disease programs in development\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cbr\u003e\u003ch2\u003eMerck \u0026amp; Co., Inc. - Marketing Mix: Place\u003c\/h2\u003e\n\u003cp\u003eMerck \u0026amp; Co., Inc. operates in more than \u003cstrong\u003e140\u003c\/strong\u003e countries and uses the MSD name outside the U.S. and Canada. Its place strategy is built around regulated, high-control channels because much of its portfolio is prescription, vaccine, or Animal Health product that cannot move through ordinary retail distribution.\u003c\/p\u003e\n\u003cp\u003eMerck reports sales across \u003cstrong\u003e5\u003c\/strong\u003e regions: United States and Canada, Europe, China, Japan, and Rest of World. That structure matters because it shows how the company organizes market access, logistics, and demand planning by geography instead of using a single global sales channel.\u003c\/p\u003e\n\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003eRegion\u003c\/th\u003e\n\u003cth\u003eReporting name\u003c\/th\u003e\n\u003cth\u003ePlace role\u003c\/th\u003e\n\u003cth\u003eDistribution emphasis\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUnited States and Canada\u003c\/td\u003e\n\u003ctd\u003eMerck\u003c\/td\u003e\n\u003ctd\u003eHome-market access\u003c\/td\u003e\n\u003ctd\u003eDirect commercial control, wholesalers, hospitals, pharmacies\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEurope\u003c\/td\u003e\n\u003ctd\u003eMSD\u003c\/td\u003e\n\u003ctd\u003eRegional market access\u003c\/td\u003e\n\u003ctd\u003eCountry-by-country distribution and reimbursement\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eChina\u003c\/td\u003e\n\u003ctd\u003eMSD\u003c\/td\u003e\n\u003ctd\u003eLocal market access\u003c\/td\u003e\n\u003ctd\u003eRegulated supply, institutional channels, local logistics\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eJapan\u003c\/td\u003e\n\u003ctd\u003eMSD\u003c\/td\u003e\n\u003ctd\u003eLocal market access\u003c\/td\u003e\n\u003ctd\u003ePharmacies, hospitals, and institutional buyers\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRest of World\u003c\/td\u003e\n\u003ctd\u003eMSD\u003c\/td\u003e\n\u003ctd\u003eBroader international coverage\u003c\/td\u003e\n\u003ctd\u003eDistributor-led access and public-sector delivery\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe global supply chain supports both human health and Animal Health, so Merck has to manage multiple delivery models in one network. That means inventory planning, temperature control, and shipment timing matter for vaccines and biologics, where product availability affects hospitals, clinics, pharmacies, veterinarians, and government buyers.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMore than \u003cstrong\u003e140\u003c\/strong\u003e countries of operation\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e5\u003c\/strong\u003e geographic sales regions\u003c\/li\u003e\n\u003cli\u003eMSD name outside the U.S. and Canada\u003c\/li\u003e\n\u003cli\u003eHuman health and Animal Health use the same global supply chain\u003c\/li\u003e\n\u003cli\u003eVaccine distribution depends on regional manufacturing and cold-chain logistics\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eRegionalizing vaccine manufacturing helps Merck align production with demand in major markets, shorten lead times, and reduce dependence on long cross-border shipments. For vaccines, place is not only where a product is sold; it is also where it is made, packed, released, and moved into local distribution channels.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eMerck \u0026amp; Co., Inc. - Marketing Mix: Promotion\u003c\/h2\u003e\n\u003cp\u003eAs of late 2025, Merck \u0026amp; Co., Inc. promotes through clinical evidence, congress visibility, regulatory milestones, and access programs. The company’s promotion is built for specialists, payers, and health systems, so trial data and approvals matter more than mass advertising.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eHeavy clinical-trial and congress readouts:\u003c\/strong\u003e Merck uses Phase 2 and Phase 3 data as the core of its promotion because each readout can extend a product’s life cycle and keep the brand in medical discussion. For oncology, ASCO is a major stage. For cardiology and cardiopulmonary disease, ACC serves the same role. That matters commercially because Keytruda generated \u003cstrong\u003e$29.5 billion\u003c\/strong\u003e in 2024 sales.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003ePromotion lever\u003c\/th\u003e\n\u003cth\u003eReal-life Merck example\u003c\/th\u003e\n\u003cth\u003eNumeric anchor\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinical readouts\u003c\/td\u003e\n\u003ctd\u003eModerna collaboration on mRNA-4157\/V940 plus Keytruda in melanoma\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e157\u003c\/strong\u003e patients; \u003cstrong\u003e49%\u003c\/strong\u003e reduction in the risk of recurrence or death\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOncology congress promotion\u003c\/td\u003e\n\u003ctd\u003eASCO presentations for Keytruda programs\u003c\/td\u003e\n\u003ctd\u003eASCO 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCardiopulmonary congress promotion\u003c\/td\u003e\n\u003ctd\u003eACC presentations supporting Winrevair\u003c\/td\u003e\n\u003ctd\u003eACC 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegulatory news\u003c\/td\u003e\n\u003ctd\u003eFDA approvals for Winrevair and Capvaxive\u003c\/td\u003e\n\u003ctd\u003e2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAccess messaging\u003c\/td\u003e\n\u003ctd\u003eMECTIZAN Donation Program\u003c\/td\u003e\n\u003ctd\u003e1987; more than \u003cstrong\u003e4 billion\u003c\/strong\u003e tablets donated\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCommercial scale\u003c\/td\u003e\n\u003ctd\u003eKeytruda\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$29.5 billion\u003c\/strong\u003e in 2024 sales\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eASCO and ACC presentations support launches:\u003c\/strong\u003e At ASCO, Merck keeps oncology assets in front of oncologists with efficacy, safety, and follow-up data. At ACC, the company keeps cardiopulmonary data in front of specialists who influence hospital adoption and formulary review. These meetings matter because they turn product claims into peer-reviewed discussion and conference coverage.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eFDA and EU filings build awareness:\u003c\/strong\u003e Merck uses regulatory milestones as promotion because filings, reviews, and approvals create news flow for physicians and payers. The 2024 FDA approvals of Winrevair and Capvaxive gave the company two launch moments tied directly to scientific evidence and label expansion. EU filings serve the same purpose by widening the market conversation beyond the U.S.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003ePartnerships with Moderna, Mayo Clinic, NVIDIA:\u003c\/strong\u003e The Moderna collaboration is the clearest promotional example because it ties Merck to personalized cancer vaccine research and a \u003cstrong\u003e157\u003c\/strong\u003e-patient Phase 2b readout. Mayo Clinic adds academic credibility in physician-facing communication, and NVIDIA adds AI credibility in discovery messaging. Those partnerships matter because they make Merck’s promotion look like clinical science, not advertising.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003ePurpose for Progress emphasizes access:\u003c\/strong\u003e Access is part of Merck’s public promotion, not a separate message. The MECTIZAN Donation Program started in \u003cstrong\u003e1987\u003c\/strong\u003e and has donated more than \u003cstrong\u003e4 billion\u003c\/strong\u003e tablets. That scale gives Merck a long-running public-health story that supports trust with governments, NGOs, and global health buyers.\u003c\/p\u003e\n\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eASCO keeps oncology data visible to specialists who prescribe Keytruda.\u003c\/li\u003e\n\u003cli\u003eACC keeps cardiopulmonary data visible to specialists who may adopt Winrevair.\u003c\/li\u003e\n\u003cli\u003eFDA approvals in \u003cstrong\u003e2024\u003c\/strong\u003e turn trial data into launch-stage awareness.\u003c\/li\u003e\n\u003cli\u003eModerna, Mayo Clinic, and NVIDIA partnerships add third-party credibility to Merck’s scientific message.\u003c\/li\u003e\n\u003cli\u003eCapvaxive is a \u003cstrong\u003e21\u003c\/strong\u003e-valent pneumococcal vaccine, and Gardasil 9 is a \u003cstrong\u003e9\u003c\/strong\u003e-valent HPV vaccine.\u003c\/li\u003e\n\u003cli\u003eThe MECTIZAN Donation Program links promotion to access with \u003cstrong\u003e1987\u003c\/strong\u003e and more than \u003cstrong\u003e4 billion\u003c\/strong\u003e tablets donated.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cbr\u003e\u003ch2\u003eMerck \u0026amp; Co., Inc. - Marketing Mix: Price\u003c\/h2\u003e\n\u003cp\u003eMerck’s price power sits mainly in patent-protected brands: \u003cstrong\u003e$25.0B\u003c\/strong\u003e from Keytruda and \u003cstrong\u003e$8.9B\u003c\/strong\u003e from Gardasil\/Gardasil 9 in \u003cstrong\u003e2023\u003c\/strong\u003e, or \u003cstrong\u003e$33.9B\u003c\/strong\u003e combined out of \u003cstrong\u003e$60.1B\u003c\/strong\u003e total revenue.\u003c\/p\u003e\n\n\u003ch3\u003ePremium pricing on patent-protected brands\u003c\/h3\u003e\n\u003cp\u003eKeytruda represented \u003cstrong\u003e41.6%\u003c\/strong\u003e of Merck’s \u003cstrong\u003e$60.1B\u003c\/strong\u003e 2023 revenue. Gardasil\/Gardasil 9 represented \u003cstrong\u003e14.8%\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eKeytruda: \u003cstrong\u003e$25.0B\u003c\/strong\u003e in 2023 sales\u003c\/li\u003e\n\u003cli\u003eGardasil\/Gardasil 9: \u003cstrong\u003e$8.9B\u003c\/strong\u003e in 2023 sales\u003c\/li\u003e\n\u003cli\u003eCombined: \u003cstrong\u003e$33.9B\u003c\/strong\u003e in 2023 sales\u003c\/li\u003e\n\u003cli\u003eShare of Merck 2023 revenue: \u003cstrong\u003e56.4%\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003ePrice driver\u003c\/th\u003e\n\u003cth\u003eReal-life data\u003c\/th\u003e\n\u003cth\u003ePricing meaning\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatent-protected oncology\u003c\/td\u003e\n\u003ctd\u003eKeytruda \u003cstrong\u003e$25.0B\u003c\/strong\u003e in 2023 sales\u003c\/td\u003e\n\u003ctd\u003ePremium pricing power\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatent-protected vaccine\u003c\/td\u003e\n\u003ctd\u003eGardasil\/Gardasil 9 \u003cstrong\u003e$8.9B\u003c\/strong\u003e in 2023 sales\u003c\/td\u003e\n\u003ctd\u003ePremium pricing power\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCompany scale\u003c\/td\u003e\n\u003ctd\u003eMerck total revenue \u003cstrong\u003e$60.1B\u003c\/strong\u003e in 2023\u003c\/td\u003e\n\u003ctd\u003eHigh-priced brands dominate the mix\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCombined concentration\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$33.9B\u003c\/strong\u003e and \u003cstrong\u003e56.4%\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003ePrice strength is concentrated in a few brands\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003ch3\u003eBiologics and specialty drugs sustain margins\u003c\/h3\u003e\n\u003cp\u003eThe main high-price drivers are the same two products: \u003cstrong\u003e$25.0B\u003c\/strong\u003e Keytruda and \u003cstrong\u003e$8.9B\u003c\/strong\u003e Gardasil\/Gardasil 9. Their combined \u003cstrong\u003e$33.9B\u003c\/strong\u003e sales in \u003cstrong\u003e2023\u003c\/strong\u003e left \u003cstrong\u003e$26.2B\u003c\/strong\u003e of Merck revenue from the rest of the portfolio.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003e$33.9B\u003c\/strong\u003e combined sales from Keytruda and Gardasil\/Gardasil 9\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e$26.2B\u003c\/strong\u003e revenue from all other Merck products in 2023\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e56.4%\u003c\/strong\u003e of 2023 revenue from two products\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3\u003eJanuvia faces IRA negotiated-price discount\u003c\/h3\u003e\n\u003cp\u003eJanuvia’s Medicare negotiated price is \u003cstrong\u003e$113.00\u003c\/strong\u003e per 30-day supply, effective \u003cstrong\u003e2026\u003c\/strong\u003e, with a \u003cstrong\u003e79%\u003c\/strong\u003e discount from the list price.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eEffective date: \u003cstrong\u003e2026\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eNegotiated price: \u003cstrong\u003e$113.00\u003c\/strong\u003e per 30-day supply\u003c\/li\u003e\n\u003cli\u003eDiscount: \u003cstrong\u003e79%\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3\u003eGeneric and biosimilar entry may compress prices\u003c\/h3\u003e\n\u003cp\u003eGeneric sitagliptin entered the U.S. market in \u003cstrong\u003e2023\u003c\/strong\u003e. That kind of entry is the clearest price pressure point on Merck’s oral diabetes franchise.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eU.S. generic sitagliptin entry: \u003cstrong\u003e2023\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eJanuvia Medicare negotiated price: \u003cstrong\u003e$113.00\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eNegotiated discount: \u003cstrong\u003e79%\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":44602234044565,"sku":"mrk-marketing-mix","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/mrk-marketing-mix.png?v=1740194560","url":"https:\/\/dcf-model.com\/es\/products\/mrk-marketing-mix","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}